Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
4.380
+0.120 (2.82%)
Jun 5, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
Immune-mediated Diseases and Cancer Therapeutics
7.00M

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
United States
7.00M